Adial Pharmaceuticals (ADIL) announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, ...
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial” or the "Company”), a clinical-stage biopharmaceutical company focused on ...
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced that patent number 12150931 was issued by the United States Patent and ...
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) – Research analysts at Litchfield Hills Research increased their ...
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of NASDAQ:ADIL opened at $1.06 on Thursday. Adial Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $4.17. The company has a fifty day moving average of $1.03 and a 200-day ...
Hosted on MSN19d
Rodman & Renshaw Initiates Coverage of Adial Pharmaceuticals (ADIL) with Buy RecommendationFintel reports that on November 14, 2024, Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (NasdaqCM:ADIL) with a Buy recommendation. Analyst Price Forecast Suggests 576.99% Upside As ...
GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a clinical-stage biopharmaceutical company, announced the completion of a pharmacokinetics study for its lead investigational drug, AD04, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback